

Sodium Iodide I 123 Diagnostic-Capsules for Oral Administration

DESCRIPTION

Sodium Iodide I 123 (Na¹²³I) for diagnostic use is supplied in capsules for oral administration. The capsules are available in strengths of 3.7 and 7.4 megabecquerels (MBq) (100 and 200 μ Ci) I 123 at time of calibration. Each capsule contains 0.3 μ g - 3 μ g Sodium Thiosulfate as a stabilizer.

The radionuclidic composition at calibration is not less than 97.0 percent I 123, not more than 2.9 percent I 125 and not more than 0.1 percent all others (I 121 or Te 121.) The radionuclidic composition at expiration time is not less than 87.2 percent I 123, not more than 12.4 percent I 125 and not more than 0.4 percent all others. The ratio of the concentration of I 123 and I 125 changes with time. Graph 1 shows the maximum concentration of each as a function of time.



Graph 1 Radionuclidic Concentration of I 123 and I 125

Physical Characteristics

Sodium Iodide I 123 decays by electron capture with a physical half-life of 13.2 hours. The photon that is useful for detection and imaging studies is listed in Table 1.

Radiation	Mean %/Disintegration	Mean Energy (keV)
Gamma-2	83.4	159
¹ Kocher, David C., Radioactive	Decay Data Tables, DOE/TIC-11026,	122, (1981)

Table 1 Principal Radiation Emission Data¹

External Radiation

The specific gamma ray constant for I 123 is 1.6 R/hr-mCi at 1 cm. The first half value thickness of lead (Pb) for I 123 is 0.005 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from the interposition of various thicknesses of Pb is shown in Table 2. For example, the use of 1.63 cm of lead will decrease the external radiation exposure by a factor of about 1,000.

Shield Thickness (Pb), cm	Coefficient of Attenuation
0.036	0.5
0.120	10 ⁻¹
0.240	10 ⁻²
0.358	10 ⁻³
0.477	10 ⁻⁴

Table 2 Radiation Attenuation by Lead Shielding²

Note that these estimates of attenuation do not take into consideration the presence of contaminants.

To correct for physical decay of I 123, the fractions that remain at selected intervals after the time of calibration are shown in Table 3.

Hours	Fraction Remaining	Hours	Fraction Remaining
0*	1.000	18	.389
3	.854	21	.332
6	.730	24	.284
9	.623	27	.242
12	.535	30	.207
15	.455		
*Time of Calibration			

Table 3 Sodium Iodide I 123 Decay Chart: Half-Life 13.2 Hours

CLINICAL PHARMACOLOGY

Sodium Iodide I 123 is readily absorbed from the upper gastrointestinal tract. Following absorption, the iodide is distributed primarily within the extracellular fluid of the body. It is trapped and organically bound by the thyroid and concentrated by the stomach, choroid plexus and salivary glands. It is excreted by the kidneys.

The fraction of the administered dose which is accumulated in the thyroid gland may be a measure of thyroid function in the absence of unusually high or low iodine intake or administration of certain drugs which influence iodine accumulation by the thyroid gland. Accordingly, the patient should be questioned carefully regarding previous medication and/or procedures involving radiographic media. Normal subjects can accumulate approximately 10-50% of the administered iodine dose in the thyroid gland, however, the normal and abnormal ranges are established by individual physician's criteria. The mapping (imaging) of Sodium Iodide I 123 distribution in the thyroid gland may provide useful information concerning thyroid anatomy and definition of normal and/or abnormal functioning of tissue within the gland.

INDICATION AND USE

Administration of Sodium Iodide I 123 is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.

CONTRAINDICATIONS

To date there are no known contraindications to the use of Sodium Iodide I 123 capsules.

WARNINGS

Females of childbearing age and children under 18 should not be studied unless the benefits anticipated from the performance of the test outweigh the possible risk of exposure to the amount of ionizing radiation associated with the test.

PRECAUTIONS

General

The contents of the capsule are radioactive. Adequate shielding of the preparation must be maintained at all times.

Do not use after the expiration time and date (30 hours after calibration time) stated on the label.

The prescribed Sodium Iodide I 123 dose should be administered as soon as practical from the time of receipt of product (i.e., as close to calibration time as possible) in order to minimize the fraction of radiation exposure due to relative increase of radionuclidic contaminants with time.

Sodium Iodide I 123, as well as other radioactive drugs, must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel. Care should also be taken to minimize radiation exposure to the patient consistent with proper patient management.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic potential, mutagenic potential, or whether Sodium Iodide I 123 affects fertility in males or females.

Pregnancy

Animal reproduction studies have not been conducted with this drug. It is also not known whether Sodium Iodide I 123 can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Sodium Iodide I 123 should be given to a pregnant woman only if clearly needed.

Ideally examinations using radiopharmaceuticals, especially those elective in nature, in women of childbearing capability should be performed during the first few (approximately ten) days following the onset of menses.

Nursing Mothers

Since I 123 is excreted in human milk, formula-feeding should be substituted for breast-feeding if the agent must be administered to the mother during lactation.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

Although rare, reactions associated with the administration of Sodium Iodide isotopes for diagnostic use include, in decreasing order of frequency, nausea, vomiting, chest pain, tachycardia, itching skin, rash and hives.

DOSAGE AND ADMINISTRATION

The recommended oral dose for the average patient (70 kg) is 3.7 to 14.8 MBq (100-400 μ Ci). The lower part of the dosage range 3.7 MBq (100 μ Ci) is recommended for uptake studies alone, and the higher part 14.8 MBq (400 μ Ci) for thyroid imaging. The determination of I 123 concentration in the thyroid gland may be initiated at six hours after administering the dose and should be measured in accordance with standardized procedures.

The patient dose should be measured by a suitable radioactive calibration system immediately prior to administration. The capsules can be utilized up to thirty (30) hours after calibration time and date. Thereafter, discard the capsules in accordance with standard safety procedures. The user should wear waterproof gloves at all times when handling the capsules or container.

Radiation Dosimetry

The estimated absorbed radiation doses to several organs of an average patient (70 kg) from oral administration of the maximum dose of 14.8 MBq (400 μ Ci) of I 123 are shown in Table 4 for thyroid uptakes of 5, 15, and 25%. For comparison at these three values of thyroid uptake, the estimated radiation doses from doses of 3.7 MBq (100 μ Ci) I 131, also used as thyroid imaging agent, are also included.

			Estimate	d Radiatio	n Absorbed I	Doses	
Target	Maximum Thyroid	I 123 mGy/14.8 MI (rads/400 μ0		8 MBq		mGy/3	131 3.7 MBq 100 μCi)
Organ	Uptake (%)	Т	OC	Т	OE		
Thyroid	5	25	(2.5)	75	(7.5)	260	(26)
	15	77	(7.7)	230	(23)	780	(78)
	25	130	(13)	410	(41)	1300	(130)
Liver	5	0.089	(0.0089)	0.13	(0.013)	0.16	(0.016)
	15	0.10	(0.010)	0.18	(0.018)	0.28	(0.028)
	25	0.11	(0.011)	0.24	(0.024)	0.41	(0.041)
Ovaries	5	0.18	(0.018)	0.19	(0.019)	0.18	(0.018)
	15	0.17	(0.017)	0.18	(0.018)	0.18	(0.018)
	25	0.16	(0.016)	0.18	(0.018)	0.17	(0.017)
Red Marrow	5	0.12	(0.012)	0.16	(0.016)	0.15	(0.015)
	15	0.12	(0.012)	0.18	(0.018)	0.21	(0.021)
	25	0.13	(0.013)	0.19	(0.019)	0.27	(0.027)

Table 4 Radiation Dose Estimates as a Function of Maximum Thyroid Uptake for I 123* SodiumIodide At Time of Calibration and Expiry Compared to I 131

Stomach Wall	5	0.96	(0.096)	0.98	(0.098)	1.7	(0.17)
	15	0.89	(0.089)	0.91	(0.091)	1.5	(0.15)
	25	0.82	(0.082)	0.85	(0.085)	1.4	(0.14)
Small Intestine	5	0.70	(0.070)	0.71	(0.071)	1.2	(0.12)
	15	0.65	(0.065)	0.67	(0.067)	1.1	(0.11)
	25	0.60	(0.060)	0.62	(0.062)	0.99	(0.099)
Testes	5	0.076	(0.0076)	0.089	(0.0089)	0.12	(0.012)
	15	0.072	(0.0072)	0.087	(0.0087)	0.12	(0.012)
	25	0.068	(0.0068)	0.085	(0.0085)	0.12	(0.012)
Bladder	5	1.7	(0.17)	1.7	(0.17)	2.9	(0.29)
	15	1.6	(0.16)	1.6	(0.16)	2.7	(0.27)
	25	1.4	(0.14)	1.5	(0.15)	2.4	(0.24)
Skeleton	5	0.11	(0.011)	0.16	(0.016)	0.12	(0.012)
	15	0.12	(0.012)	0.18	(0.018)	0.18	(0.018)
	25	0.14	(0.014)	0.21	(0.021)	0.24	(0.024)
Total Body	5	0.11	(0.011)	0.16	(0.016)	0.24	(0.024)
	15	0.14	(0.014)	0.25	(0.025)	0.47	(0.047)
	25	0.17	(0.017)	0.35	(0.035)	0.70	(0.070)

*Concentration at Time of Calibration: 97% I 123, 2.9% I 125, 0.1% Te 121

Concentration at Time of Expiry: 87.2% I 123, 12.4% I 125, 0.4% Te 121

All Iodine Kinetics treated as in MIRD Dose Estimate Report 5. Bladder voiding interval, 4.8 hours. Tellurium 121 dosimetry taken from ICRP 30.

HOW SUPPLIED

Sodium Iodide I 123 is supplied as capsules for oral administration in strengths of 3.7 MBq (100 μ Ci) and 7.4 MBq (200 μ Ci) at time of calibration. Each gelatin capsule contains 0.45 - 0.65 g of sucrose. The capsules are packaged in plastic vials containing either one or five capsules of a single strength per vial. The plastic vial is packaged in a lead shield with a label identical to that affixed to the plastic vial. A package insert is supplied with each lead shield.

The -I (Iodine) content for a 100 μ Ci capsule is 5.2 ng and the -I content for a 200 μ Ci capsule is 10.4 ng at TOC.

Dispense and preserve capsules in well-closed containers that are adequately shielded. Store at room temperature, below 86°F.


The contents of the capsules are radioactive. Adequate shielding and handling precautions must be maintained.

THIS PACKAGE INSERT ISSUED APRIL 2018

CardinalHealth Denver, CO 80011 (303) 343-6800

Sodium Iodide I 123 1-020-16

PRINCIPAL DISPLAY PANEL - 100 µCi CAPSULE



100 µCi Capsule

CardinalHealth

Denver, CO 80011

NUMBER OF CAPSULES: 1

ASSAY: 3.7 MBq (100 uCi) Per Capsule

TOTAL ACTIVITY: 3.7 MBq (100 uCi)

CALIB. DATE:

CALIB. TIME:

BATCH NO.:

SODIUM IODIDE I 123 3.7 MBq (100 uCi) CAPSULES DIAGNOSTIC FOR ORAL USE ONLY

EXPIRATION: 30 hours from the Date and Time of Calibration.

Rx only


READ PACKAGE INSERT FOR DIRECTIONS FOR USE.

Iodine 123 Radioactive Half-life 13.2 hours, carrier free. Calculate correct dosage from Date and

Time of Calibration STORE AT ROOM TEMPERATURE (BELOW 86° F) CAUTION RADIOACTIVE MATERIAL

1-001-10

PRINCIPAL DISPLAY PANEL - 200 µCi CAPSULE



200 µCi Capsule

CardinalHealth

Denver, CO 80011

NUMBER OF CAPSULES: 1

ASSAY: 7.4 MBq (200 uCi) Per Capsule

TOTAL ACTIVITY: 7.4 MBq (200 uCi)

CALIB. DATE:

CALIB. TIME:

BATCH NO.:

SODIUM IODIDE I 123 7.4 MBq (200 uCi) CAPSULES DIAGNOSTIC FOR ORAL USE ONLY

EXPIRATION: 30 hours from the Date and Time of Calibration.

Rx only

READ PACKAGE INSERT FOR DIRECTIONS FOR USE. Iodine 123 Radioactive Half-life 13.2 hours, carrier free. Calculate correct dosage from Date and Time of Calibration

STORE AT ROOM TEMPERATURE (BELOW 86° F)

CAUTION RADIOACTIVE MATERIAL

1-002-10

Product Informa	ition						
Product Type		HUMAN PRESCRIPTION D	RUG	Item Code (S	ource)	NDC:488	315-1001
Route of Administr	ation	ORAL					
Active Ingredier	nt/Active Moio	ety					
	Ir	ıgredient Name			Basis of S	Strength	Strength
SO DIUM IO DIDE I-12	3 (UNII: 29 UKX3	A616) (IODIDE ION I-123 -	UNII:98QPV8	670C)	IODIDE ION	I-123	100 uCi
Inactive Ingredi	ents						
Inactive Ingredi	ents						
		Ingredient Name				Stre	ngth
SUCROSE (UNII: C15)	LH8 M554)	-				Stre	ngth
SUCROSE (UNII: C15 SODIUM THIOSULF	LH8 M554) ATE (UNII: HX103	-				Stre	ngth
SUCROSE (UNII: C15 SODIUM THIOSULF Product Charact	LH8 M554) ATE (UNII: HX103	32V43M)	Score			Stre no score	ngth
SUCROSE (UNII: C15 SODIUM THIOSULF Product Charact Color	1H8 M554) ATE (UNII: HX103 e ristics	32V43M)	Score Size				ngth
SUCROSE (UNII: C15 SODIUM THIOSULF Product Charact Color Shape	LH8 M554) ATE (UNII: HX103 eristics PURPLE, GI	32V43M)		ode		no score	ngth
Inactive Ingredie SUCROSE (UNII: C15 SODIUM THIOSULF Product Charact Color Shape Flavor Contains	LH8 M554) ATE (UNII: HX103 eristics PURPLE, GI	32V43M)	Size	ode		no score	ngth
SUCROSE (UNII: C15 SODIUM THIOSULF Product Charact Color Shape Flavor	LH8 M554) ATE (UNII: HX103 eristics PURPLE, GI	32V43M)	Size	ode		no score	ngth
SUCROSE (UNII: C15 SODIUM THIOSULF Product Charact Color Shape Flavor Contains	LH8 M554) ATE (UNII: HX103 eristics PURPLE, GI	32V43M)	Size	ode		no score	ngth
SUCROSE (UNII: C15 SODIUM THIOSULF Product Charact Color Shape Flavor Contains Packaging	IH8 M554) ATE (UNII: HX 10 3 eristics PURPLE, GI CAPSULE	32V43M) RAY	Size		Start Date	no score 20mm	
SUCROSE (UNII: C15 SODIUM THIOSULF Product Charact Color Shape Flavor Contains Packaging	IH8 M554) ATE (UNII: HX103 eristics PURPLE, GI CAPSULE	32V43M)	Size	ode Marketing \$ 01/02/2003	Start Date	no score 20mm	
SUCROSE (UNII: C15 SODIUM THIOSULF Product Charact Color Shape Flavor Contains Packaging # Item Code	IH8 M554) ATE (UNII: HX103 eristics PURPLE, GI CAPSULE	32V43M) RAY	Size Imprint C	Marketing S 01/02/2003	Start Date	no score 20mm	
SUCROSE (UNII: C15 SODIUM THIOSULF Product Charact Color Shape Flavor Contains Packaging # Item Code 1 NDC:48815-1001-1	HB M554) ATE (UNII: HX103 eristics PURPLE, GI CAPSULE	B2V43M) RAY Package Description	Size Imprint C	Marketing S 01/02/2003	Start Date	no score 20mm	

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA018671	0 1/0 2/20 0 3	

	IDE I 123						
odium iodide i 123	capsule, gelati	n coated					
Product Informa	ition						
Product Type		HUMAN PRESCRIPTION DRU	G	Item Code (S	ource)	NDC:488	15-1002
Route of Administra	ation	ORAL					
Active Ingredien	ıt/Active Moi	ety					
U		igredient Name			Basis of S	Strength	Strength
SODIUM IODIDE I-12		A6 16) (IODIDE ION I-123 - UN	II:98QPV8	670C)	IODIDE ION	_	200 uCi
Inactive Ingredie	ents	Ingredient Name				Stre	ngth
		Ingredient Name				Stre	ngth
SUCROSE (UNII: C151							
SO DIUM THIO SULFA	ATE (UNII: HX103	32V43M)					
Product Charact	eristics						
Color	BLUE, ORA	NGE	Score			no score	
Shape	CAPSULE		Size			20 mm	
Flavor			T • •				
Cantaina			Imprint	Code			
Contains			Imprint	Code			
Contains			Imprint	Code			
			Imprint	Code			
Packaging		Package Description	Imprint	Code Marketing	Start Date	Marketin	g End Date
Beckaging # Item Code 1 NDC:48815-1002-1	1 in 1 CAN			Marketing 01/02/2003	Start Date	Marketin	g End Date
Example by the sector of the sector	1 in 1 CAN 1 in 1 VIAL, PLA	Package Description STIC; Type 0: Not a Combination		Marketing 01/02/2003 t	Start Date	Marketin	g End Date
First start	1 in 1 CAN 1 in 1 VIAL, PLA 1 in 1 CAN	STIC; Type 0: Not a Combinatio	on Product	 Marketing 01/02/2003 01/02/2003 	Start Date	Marketin	g End Date
1 NDC:48815-1002-1 1	1 in 1 CAN 1 in 1 VIAL, PLA 1 in 1 CAN		on Product	 Marketing 01/02/2003 01/02/2003 	Start Date	Marketin	g End Date
Particular Set	1 in 1 CAN 1 in 1 VIAL, PLA 1 in 1 CAN	STIC; Type 0: Not a Combinatio	on Product	 Marketing 01/02/2003 01/02/2003 	Start Date	Marketin	g End Date
P=ckaging # Item Code 1 NDC:48815-1002-1 1 2 NDC:48815-1002-5	1 in 1 CAN 1 in 1 VIAL, PLA 1 in 1 CAN 5 in 1 VIAL, PLA	STIC; Type 0: Not a Combinatio	on Product	 Marketing 01/02/2003 01/02/2003 	Start Date	Marketin	g End Date
Particular Series Item Code	1 in 1 CAN 1 in 1 VIAL, PLA 1 in 1 CAN 5 in 1 VIAL, PLA	STIC; Type 0: Not a Combinatio	on Product	 Marketing 01/02/2003 01/02/2003 			g End Date g End Date

Labeler - Cardinal Health 418, Inc (149029253)